Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce preliminary results for the fiscal 2026 fourth quarter. PRELIMINARY FISCAL 2026 FOURTH QUARTER HIGHLIGHTS – ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results